This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Cell & Gene Therapy Manufacturing & Commercialization Europe
Save the Date: 2-4 December 2024
Convention Centre DublinDublin, Ireland

Karen Pinachyan
Head of Global Medical Affairs Hematology at CSL Behring
Speaker

Profile

Karen Pinachyan, MD is the Head of Global Medical Affairs for the Haematology Therapeutic Area at CSL Behring. In this position, he overseas medical affairs strategy and activities for their congenital and acquired bleeding disorder’s portfolio, as well as a commercialised gene therapy product, and several pipeline products.

Karen did his otolaryngology and head & neck surgery residency in Marseille, France, where he obtained a Masters degree in management and a diploma in public health, where both thesis focused on orphan drug development incentives and its importance for healthcare systems, patient community and the biotechnology industry.

Karen joined the industry at a biotechnology startup company active in the field of peripheral neuropathies, and successfully led the application for Orphan Drug Designation for the lead compound for both the European Medicines Agency and US FDA.

Agenda Sessions

  • What could we learn from commercialising a gene therapy in Europe for haemophilia B?

    09:50